Stephanie K. Dougan, Ph.D.
Affiliations: | 2007 | Harvard University, Cambridge, MA, United States |
Google:
"Stephanie Dougan"Mean distance: 13.09
Parents
Sign in to add mentorRichard S. Blumberg | grad student | 2007 | Harvard | |
(The role of MTP in CD1d antigen presentation and NKT cell development.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Huang YH, Zhu C, Kondo Y, et al. (2024) Author Correction: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature |
Kureshi R, Bello E, Kureshi CTS, et al. (2023) DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity. Science Advances. 9: eadk1853 |
Kurmi K, Liang D, van de Ven R, et al. (2023) Metabolic modulation of mitochondrial mass during CD4 T cell activation. Cell Chemical Biology |
Ventre KS, Roehle K, Bello E, et al. (2023) cIAP1/2 Antagonism Induces Antigen-Specific T Cell-Dependent Immunity. Journal of Immunology (Baltimore, Md. : 1950) |
Quijano-Rubio A, Bhuiyan AM, Yang H, et al. (2022) A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nature Biotechnology |
Stump CT, Roehle K, Manjarrez Orduno N, et al. (2021) Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Open Biology. 11: 210245 |
Roehle K, Qiang L, Ventre KS, et al. (2021) cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Science Translational Medicine. 13 |
Heckler M, Ali LR, Clancy-Thompson E, et al. (2021) Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discovery |
Luoma AM, Suo S, Williams HL, et al. (2020) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell |
Crowley SJ, Bruck PT, Bhuiyan MA, et al. (2020) Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology. 10: 190235 |